Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

During aging, the cellular milieu of the brain exhibits tell-tale signs of compromised
bioenergetics, impaired adaptive neuroplasticity and resilience, aberrant neuronal network …

Importance Network hyperexcitability may contribute to cognitive dysfunction in patients with
Alzheimer disease (AD). Objective To determine the ability of the antiseizure drug …

Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

Our incomplete understanding of the link between Alzheimer's Disease pathology and
symptomatology is a crucial obstacle for therapeutic success. Recently, translational studies …

It is increasingly accepted that early cognitive impairment in Alzheimer's disease results in
considerable part from synaptic dysfunction caused by the accumulation of a range of …

Accumulation of misfolded and aggregated forms of tau protein in the brain is a
neuropathological hallmark of tauopathies, such as Alzheimer's disease and frontotemporal …

Alzheimer's disease (AD) is the most common form of dementia. AD brain pathology starts
decades before the onset of clinical symptoms. One early pathological hallmark is blood …

Neuronal networks with strong recurrent connectivity provide the brain with a powerful
means to perform complex computational tasks. However, high-gain excitatory networks are …

There is currently no established therapy to treat or prevent Alzheimer's disease. The
ketogenic diet supplies an alternative cerebral metabolic fuel, with potential neuroprotective …